Biomarkers involved in evaluation of platelets function in South-Eastern Romanian patients with hematological malignancies subtypes.
Aged
Biomarkers, Tumor
/ blood
Blood Platelets
/ immunology
CD3 Complex
/ blood
Cell Adhesion
/ immunology
Cell-Derived Microparticles
Female
Flow Cytometry
Humans
Integrin beta3
/ blood
Leukemia, Myeloid, Acute
/ blood
Lymphocyte Activation
Lymphocyte Count
Lymphoma, B-Cell
/ blood
Male
Middle Aged
Platelet Activation
/ immunology
Platelet Count
Platelet Glycoprotein GPIb-IX Complex
/ analysis
Romania
T-Lymphocytes, Helper-Inducer
/ immunology
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
21 May 2021
21 May 2021
Historique:
received:
14
10
2020
accepted:
23
04
2021
entrez:
20
5
2021
pubmed:
21
5
2021
medline:
27
5
2021
Statut:
ppublish
Résumé
At present, various researches presented how subtypes of hematological malignancies are related to stages of the immune response, because the activated immune system represents a promising form in cancer treatment. This study explores the relationship between the adaptive immune system (T cells), and the coagulation system (platelets, platelet membrane glycoproteins, platelets derivate microparticles) which seems to play an important role in host immune defense of patients with acute myeloblastic leukemia (AML) or B cell lymphoma (BCL), 2 of the most common hematological malignancies subtypes.Blood samples (n = 114) obtained from patients with AML or BCL were analyzed for platelet membrane glycoproteins (CD42b, CD61), glycoprotein found on the surface of the T helper cells (CD4+), protein complex-specific antigen for T cells (CD3+), platelet-derived microparticles (CD61 PMP) biomarkers by flow cytometry, and hematological parameters were quantified by usual methods.In patients with AML, the means of the percentage of the expressions of the molecules on platelet surfaces (CD61 and CD42b, P < .01; paired T test) were lower as compared to both control subgroups. The expression of cytoplasmic granules content (CD61 PMP) had a significantly higher value in patients with AML reported to controlling subgroups (P < .01; paired T test), which is suggesting an intravascular activation of platelets.The platelet activation status was presented in patients with low stage BCL because CD61 and CD42b expressions were significantly higher than control subgroups, but the expression of CD 61 PMP had a significantly decreased value reported to control subgroups (all P < .01; paired T test). T helper/inducer lineage CD4+ and T lymphoid lineage CD3+ expressions presented significant differences between patients with AML or low stage BCL reported to control subgroups (all P < .01; paired T test).Platelet-lymphocyte interactions are involved in malignant disorders, and CD61, CD42b present on platelet membranes, as functionally active surface receptors mediate the adhesion of active platelets to lymphocytes, endothelial cells, and cancer cells.
Identifiants
pubmed: 34011073
doi: 10.1097/MD.0000000000025944
pii: 00005792-202105210-00054
pmc: PMC8137019
doi:
Substances chimiques
Biomarkers, Tumor
0
CD3 Complex
0
ITGB3 protein, human
0
Integrin beta3
0
Platelet Glycoprotein GPIb-IX Complex
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25944Subventions
Organisme : Ovidius University of Constanta
ID : CNFIS-FDI-2019-0558 project
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
PLoS One. 2010 Jul 22;5(7):e11469
pubmed: 20661468
Crit Rev Oncol Hematol. 2004 Jan;49(1):1-35
pubmed: 14734152
Thromb Haemost. 2001 Apr;85(4):639-46
pubmed: 11341498
J Immunol. 2006 Feb 1;176(3):1534-42
pubmed: 16424182
J Extracell Vesicles. 2016 Apr 15;5:25355
pubmed: 27086589
J Egypt Natl Canc Inst. 2019 Nov 1;31(1):3
pubmed: 32372156
AIDS. 2015 Jul 17;29(11):1297-308
pubmed: 26002800
Platelets. 2014;25(8):612-8
pubmed: 24433232
Eur J Haematol. 2014;92(5):367-76
pubmed: 24400878
Am J Clin Pathol. 2018 Oct 01;150(5):461-467
pubmed: 30052718
Lancet. 2000 Apr 29;355(9214):1531-9
pubmed: 10801186
Blood. 2007 Jun 1;109(11):4786-92
pubmed: 17303692
Gastroenterology. 2005 Jun;128(7):1796-804
pubmed: 15940614
Mol Biol Rep. 2020 Apr;47(4):2509-2519
pubmed: 32088817
Cancer Cell. 2011 Jun 14;19(6):715-27
pubmed: 21665146
Br J Haematol. 2009 Jul;146(2):150-7
pubmed: 19466975
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Platelets. 2013;24(1):63-70
pubmed: 22372532
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Blood. 2000 Feb 1;95(3):930-5
pubmed: 10648405
J Leukoc Biol. 2013 Sep;94(3):521-9
pubmed: 23801652
Clin Cancer Res. 2005 Feb 1;11(3):1010-20
pubmed: 15709166
Am J Respir Crit Care Med. 2008 Dec 1;178(11):1148-55
pubmed: 18723433
Haematologica. 2012 Jun;97(6):895-902
pubmed: 22271903
Pediatr Blood Cancer. 2017 Oct;64(10):
pubmed: 28333411
Br J Haematol. 2013 Nov;163(3):413-4
pubmed: 23952106
J Exp Med. 2002 May 20;195(10):1303-16
pubmed: 12021310
Mediterr J Hematol Infect Dis. 2010 Aug 13;2(3):e2010023
pubmed: 21415976
Thromb Haemost. 2009 Apr;101(4):748-54
pubmed: 19350121
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28766841
Clin Exp Immunol. 2013 Jan;171(1):36-45
pubmed: 23199321
Lab Hematol. 2003;9(3):132-7
pubmed: 14521319
Thromb Res. 2004;113(6):379-85
pubmed: 15226092
Eur Urol. 2009 Sep;56(3):479-84
pubmed: 18585841
Cancer Res. 2011 Mar 1;71(5):1540-9
pubmed: 21212409
Hematol Oncol Clin North Am. 2013 Jun;27(3):381-409
pubmed: 23714305
Crit Care Med. 2005 Nov;33(11):2540-6
pubmed: 16276178
Thromb Res. 2000 Oct 1;100(1):27-34
pubmed: 11053613
Genet Mol Res. 2015 Dec 07;14(4):16074-89
pubmed: 26662400
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
EJIFCC. 2013 Jan 16;23(4):124-34
pubmed: 27683428
Eur Heart J. 2001 Sep;22(17):1561-71
pubmed: 11492985
J Proteome Res. 2012 Dec 7;11(12):5611-29
pubmed: 23082778
Proteomics. 2011 Jul;11(13):2745-51
pubmed: 21630462
Nat Rev Immunol. 2011 Apr;11(4):264-74
pubmed: 21436837
J Immunol. 2008 Oct 15;181(8):5242-8
pubmed: 18832678
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
J Thromb Haemost. 2011 Feb;9(2):237-49
pubmed: 21040448
Clin Cancer Res. 2005 Dec 1;11(23):8226-9
pubmed: 16322278
Nat Med. 2005 Nov;11(11):1167-9
pubmed: 16258538
Biom J. 2009 Jun;51(3):475-90
pubmed: 19588455
Platelets. 2000 May;11(3):183-4
pubmed: 10938896
J Investig Med. 2021 Feb;69(2):333-337
pubmed: 33172871
Br J Cancer. 2012 Feb 14;106(4):768-74
pubmed: 22240788
Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2341-9
pubmed: 21071698